April 1, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Evaxion Biotech (EVAX-NASDAQ)

EVAX: Company Lays Out Ambitious 2025 Plan

EVAX is using well-developed AI technology in the pursuit of important treatments. We value EVAX at $19.75 using discounted cash flow analysis with a 10% discount rate.

Current Price (03/31/25)	$1.85
Valuation	**$19.75**

OUTLOOK

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments. The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.

The company released its full-year 2024 results and updated investors on the tremendous progress made. With the timeline laid out by the company, we believe 2025 will be an exciting year for EVAX.

SUMMARY DATA

52-Week High	**$21.55**
52-Week Low	**$1.75**
One-Year Return (%)	**-88.54**
Beta	**-0.25**
Average Daily Volume (sh)	**68**
Shares Outstanding (mil)	**6.3**
Market Capitalization ($mil)	**$11.7**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**11**
Insider Ownership (%)	**42**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2024 Estimate	**N/A**
P/E using 2025 Estimate	**N/A**

Risk Level	**Above Avg.**
Type of Stock	**Biotech**

ZACKS ESTIMATES

Revenue
(in thousands of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	73 A
2024	51 A	154 A	3017 A	122 A	3344 A
2025	120 E	125 E	120 E	123 E	488 E
2026	220 E	250 E	300 E	206 E	976 E

Earnings per Share (USD)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	-0.81 A
2024	0.03 A	-0.12 A	-0.04 A	-0.07 A	-0.20 A
2025	-0.65 E	-0.45 E	-0.80 E	-0.88 E	-2.78 E*
2026	-0.70 E	-0.70 E	-0.65 E	-0.70 E	-2.75 E

* ADS ratio was changed in Q1 2025.

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

Update

Evaxion (EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it commonly takes with standard drug discovery methods. The use of AI also allows the company to decrease the risk of failure as the technology filters out those results that may result in low efficacy or unacceptable toxicity.

Company management recently released full-year 2024 results that showed the company made tremendous progress during the year, which we've written about, and outlined a 2025 plan that is ambitious and exciting for investors. Most importantly, due to capital market actions that we've discussed, the company has enough cash to last to mid-2026, great news for investors that may be concerned about dilution.

Company management also recently announced that it is extending its Phase 2 trial of EVX-01 in order to gather additional data that may lead to enhanced treatments. As a reminder, EVX-01 is the company's lead clinical asset. EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. As a result of the positive results seen to this point, some of which are described below, the company is adding a year to the trial in order to get more data and determine if there is an opportunity for enhanced treatments. This is an extremely positive development and does nothing to slow down the progress of the Phase 2 trial. The current trial is investigating EVX-01 in combination with Keytruda in patients with advanced melanoma. That trial will continue as scheduled, but trial participants will now be given the opportunity to continue to a third year of treatment using EVX-01 as a stand alone treatment.

The company has decided to add the additional year due to the good results seen thus far and the belief that EVX-01 may be even more effective than initially believed. The additional year, according to company management, will not affect the cost structure or require additional fund raises—so we strongly believe this is a win-win for investors. Company management noted that investors will get 2-year data from the trial in the second half of 2025.

As a reminder, EVX-01 triggered a 79% tumor-specific response, a substantial increase from the 58% response rate seen in the Phase I trial. As we've talked about in previous reports, the AI-Immunology platform of Evaxion showed the promise of improving treatment for patients by being able to "learn" from previous trials and improve upon the treatment as it moves along the approval process. These results are further confirmation of the vast potential that this platform has and illustrate why we continue to have a very positive view on the company.


Company management also noted that the company expects to use its proprietary AI-Immunology to identify two new vaccine candidates for infectious diseases in 2025—further broadening the company's pipeline.

We continue to be excited about the investment opportunities offered by EVAX. In our view, these announcements are the tip of the iceberg of what the AI platforms developed by Evaxion can achieve and positive news will continue to come out as we move forward. We suggest investors investigate EVAX further and consider investing, as we believe the company is at an inflection point that is the start of sustained uptrend.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Evaxion Pharmaceuticals Income Statement and Balance Sheet							
	(In thousands, except per share data)						
	2023A	**1Q2024A**	**2Q2024A**	**3Q2024A**	**4Q2024A**	**2025E**	**2026E**
Revenue	73	51	154	3,017	122	488	976
Operating Costs:							
Research and Development	(11,916)	(2,836)	(2,752)	(2,614)	(2,255)	(12,035)	(12,156)
General and Admistrative	(10,354)	(1,611)	(1,983)	(2,134)	(1,891)	(7,564)	(7,942)
Total Operating Gain/(Loss)	(22,197)	(4,396)	(4,581)	(1,731)	(4,024)	(19,111)	(19,122)
Finance Income	963	5,618	220	84	578	2,312	2,428
Finance Expenses	(1,681)	(246)	(2,036)	(384)	(458)	(1,832)	(1,924)
Other Income/(Expenses)	-	-	-	-	-	-	-
Income Tax Benefit	790	218	199	96	275	1,100	1,155
Net Gain/(Loss)	(22,125)	1,194	(6,198)	(1,935)	(3,629)	(17,531)	(17,463)
Basic and diluted loss per share	(0.81)	0.03	(0.12)	(0.04)	(0.07)	(2.78)	(2.74)
Common Shares Outstanding	27,335,829	48,638,239	53,787,469	55,255,329	53,644,483	6,300,000	6,363,000
Assets							
Current Assets							
Cash and cash equivalents	5,583	11,731	7,993	4,576	5,952	7,012	7,082
Other Assets	7,306	10,923	7,238	10,609	6,533	6,598	6,664
Total Assets	12,889	22,654	15,231	15,185	12,485	13,610	13,746
Liabilities and SH deficit (equity)							
Total Liabilities	17,618	20,050	13,978	15,111	14,137	14,278	14,421
Share Capital	5,899	7,964	8,244	8,732	10,516	10,621	10,727
Other Reserves	99,946	109,602	105,983	106,245	106,369	107,433	108,507
Accumulated Deficit	(107,860)	(112,033)	(112,974)	(114,903)	(118,537)	(118,722)	(119,910)
Effect from der. Liab. From warrants	(2,714)	(2,929)	0	0	0	0	0
Total SH deficit/(equity)	(4,729)	2,604	1,253	74	(1,652)	(669)	(675)
Total Liabilities and SH deficit/(equity)	12,889	22,654	15,231	15,185	12,485	13,610	13,746

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.